ClinicalTrials.gg
CompletedNCT00191139Updated Feb 17, 2010Results posted

Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of gemcitabine and docetaxel in Non-small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-02-17.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 5 under way, none of them phase 3. Gemcitabine · Carcinoma, Non-Small-Cell Lung.

Enrollment
67th of 152
64 · median 53
Started
2003
with 17 others
Phase 2
109 of 169
4 open now
Registered
49th of 169
by date
Lead sponsor
21 of 169
Eli Lilly and Company

Among the 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung, this one is the 67th largest by enrollment of the 152 interventional ones that give a count, is one of 18 that started in 2003, is one of 109 in phase 2, and was the 49th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • histologic or cytologic proof of single primary non-small cell lung cancer
  • No prior chemotherapy or radiation therapy
  • no prior

Exclusion criteria

Exclusion Criteria:

  • pregnancy or breastfeeding
  • serious concomitant systemic disorder
  • unintentional weight loss greater than 10%
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Gemcitabine

    Drug: gemcitabine · Drug: cisplatin · Drug: etoposide · Radiation: radiation therapy

  • Experimental
    Gemcitabine plus Docetaxel

    Drug: gemcitabine · Drug: docetaxel · Drug: cisplatin · Drug: etoposide · Radiation: radiation therapy

Interventions

  • After induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In both treatment arms, gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles.

    Also known as: LY188011, Gemzar

  • Following cisplatin-etoposide induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In this treatment arm, docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine.

    Also known as: Taxotere

  • As part of induction chemotherapy, cisplatin is given 50 mg/m2, IV, day 1, 8, 29 and 36 (spans 2 cycles)

    Also known as: Platinol, Platinol-AQ, CDDP

  • As part of induction chemotherapy, etoposide is given 50 mg/m2, IV, days 1-5 and 29-33 (spans 2 cycles)

    Also known as: Toposar®, VePesid®, Etopophos®, VP-16, Etoposide phosphate

  • Radiationradiation therapy

    In conjunction with induction chemotherapy, radiation therapy is administered at a dose of 200 centi Gray (cGy) per day, Monday through Friday for 6 weeks

06

What researchers measure

Primary outcomes

  1. 2-Year Survival

    Percentage of participants alive at 2 years.

    Time frame: 2 years

Secondary outcomes

  1. Number of Patients With Overall Tumor Response

    Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target lesions; Partial Response (PR) =30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) =20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes that do not meet above criteria. The total number of CRs plus PRs equals overall response rate (ORR).

    Time frame: randomization and every 3 months up to 2 years of post-study followup

  2. Progression-Free Survival

    Defined as the time from randomization into consolidation treatment to the first date of documented disease progression or death. Progression-free survival time was censored at the date of the last follow-up visit at which disease was assessed for patients who were still alive and who had not progressed.

    Time frame: baseline to measured progressive disease up to 2057 days

  3. Overall Survival

    Overall survival is the duration from enrollment to death from any cause. For patients who are alive, overall survival is censored at the last contact.

    Time frame: baseline to date of death from any cause up to 2057 days

  4. Lung Cancer Symptom Scale (LCSS) Assessment Post-randomization

    LCSS measures physical \& functional dimensions. The patient scale contains 9 items, 3 summation \& 6 symptom items. Each item is marked on a visual analog scale (0=low; 100=high). The mean of the 6 symptoms is used to calculate the average symptom burden index (ASBI). Improved=mean ASBI assessments from any 2 consecutive improved post-randomization assessments was at least 0.5 standard deviation (SD) below pre-randomization ASBI; worse=mean ASBI from any 2 consecutive post-randomization assessments was at least 0.5 SD above pre-randomization ASBI; stable=criteria for improved/worse not met.

    Time frame: baseline to 3 months after last dose of study treatment (three 21-day cycles)

07

Results

Posted Dec 25, 2009

Participant flow

Participant flow — Overall Study
MilestoneGemcitabineGemcitabine Plus Docetaxel
Started3232
Completed2720
Not completed512
Withdrew: Adverse event26
Withdrew: Death20
Withdrew: Withdrawal by subject03
Withdrew: Disease progression01
Withdrew: Other12

Outcome measures

Primary2-Year Survival

Percentage of participants alive at 2 years.

Time frame:
2 years
Reported as:
Number · percentage of participants
2-Year Survival
percentage of participantsGemcitabineGemcitabine Plus Docetaxel
2-Year Survival40.655.7
Statistical analysis
  • Gemcitabine · normal approximation · Survival rate: 40.6 · 95% CI 23.8 to 56.8Count the number of surviving participants at each time interval to get survival rates.
  • Gemcitabine Plus Docetaxel · normal approximation · Survival rate: 55.7 · 95% CI 36.8 to 70.9Count the number of surviving participants at each time interval to get survival rates.
SecondaryNumber of Patients With Overall Tumor Response

Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target lesions; Partial Response (PR) =30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) =20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes that do not meet above criteria. The total number of CRs plus PRs equals overall response rate (ORR).

Time frame:
randomization and every 3 months up to 2 years of post-study followup
Reported as:
Number · participants
Number of Patients With Overall Tumor Response
participantsGemcitabineGemcitabine Plus Docetaxel
Number of Patients With Overall Tumor Response2427
Statistical analysis
  • Gemcitabine · normal approximation · Response rate: 75 · 95% CI 56.6 to 88.5
  • Gemcitabine Plus Docetaxel · Normal approximation · Response rate: 84.4 · 95% CI 67.2 to 94.7
SecondaryProgression-Free Survival

Defined as the time from randomization into consolidation treatment to the first date of documented disease progression or death. Progression-free survival time was censored at the date of the last follow-up visit at which disease was assessed for patients who were still alive and who had not progressed.

Time frame:
baseline to measured progressive disease up to 2057 days
Reported as:
Median · days
Progression-Free Survival
daysGemcitabineGemcitabine Plus Docetaxel
Progression-Free Survival162.5 (82.0 to 239.0)408.0 (141.0 to 708.0)
Statistical analysis
  • Gemcitabine vs Gemcitabine Plus Docetaxel · Log Rank · p = 0.08
SecondaryOverall Survival

Overall survival is the duration from enrollment to death from any cause. For patients who are alive, overall survival is censored at the last contact.

Time frame:
baseline to date of death from any cause up to 2057 days
Reported as:
Median · days
Overall Survival
daysGemcitabineGemcitabine Plus Docetaxel
Overall Survival492.5 (299.0 to 1034.0)899.0 (498.0 to 1583.0)
Statistical analysis
  • Gemcitabine vs Gemcitabine Plus Docetaxel · Log Rank · p = 0.38
SecondaryLung Cancer Symptom Scale (LCSS) Assessment Post-randomization

LCSS measures physical \& functional dimensions. The patient scale contains 9 items, 3 summation \& 6 symptom items. Each item is marked on a visual analog scale (0=low; 100=high). The mean of the 6 symptoms is used to calculate the average symptom burden index (ASBI). Improved=mean ASBI assessments from any 2 consecutive improved post-randomization assessments was at least 0.5 standard deviation (SD) below pre-randomization ASBI; worse=mean ASBI from any 2 consecutive post-randomization assessments was at least 0.5 SD above pre-randomization ASBI; stable=criteria for improved/worse not met.

Time frame:
baseline to 3 months after last dose of study treatment (three 21-day cycles)
Reported as:
Number · participants
Lung Cancer Symptom Scale (LCSS) Assessment Post-randomization
participantsGemcitabineGemcitabine Plus Docetaxel
Improvement85
Stable109
Worse28

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemcitabine—13/32 (40.6%)32/32 (100%)
Gemcitabine Plus Docetaxel—18/32 (56.3%)32/32 (100%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventGemcitabineGemcitabine Plus Docetaxel
Pneumonia NOSInfections and infestations4/325/32
Anaemia NOSBlood and lymphatic system disorders0/324/32
DehydrationMetabolism and nutrition disorders0/324/32
Pneumonitis NOSRespiratory, thoracic and mediastinal disorders1/323/32
Febrile neutropeniaBlood and lymphatic system disorders2/322/32
ThrombocytopeniaBlood and lymphatic system disorders1/322/32
NauseaGastrointestinal disorders1/322/32
Oesophagitis NOSGastrointestinal disorders1/322/32
Death NOSGeneral disorders2/320/32
PyrexiaGeneral disorders1/322/32
Most frequent other events
Showing 10 of 94
Most frequent other events
EventGemcitabineGemcitabine Plus Docetaxel
NauseaGastrointestinal disorders23/3228/32
FatigueGeneral disorders19/3226/32
Anaemia NOSBlood and lymphatic system disorders18/3224/32
NeutropeniaBlood and lymphatic system disorders19/3223/32
Vomiting NOSGastrointestinal disorders17/3222/32
AlopeciaSkin and subcutaneous tissue disorders14/3220/32
AnorexiaMetabolism and nutrition disorders16/3217/32
CoughRespiratory, thoracic and mediastinal disorders17/3216/32
Diarrhoea NOSGastrointestinal disorders9/3216/32
DyspnoeaRespiratory, thoracic and mediastinal disorders14/3216/32

Baseline characteristics

Age Continuous
Age Continuous(years)GemcitabineGemcitabine Plus DocetaxelTotal
Median59.5 ± 7.3159.5 ± 9.6159.5 ± 8.48
Sex: Female, Male
Sex: Female, Male(Participants)GemcitabineGemcitabine Plus DocetaxelTotal
Female5611
Male272653
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)GemcitabineGemcitabine Plus DocetaxelTotal
Caucasian181937
Black123
Asian131023
Hispanic011
Region of Enrollment
Region of Enrollment(participants)GemcitabineGemcitabine Plus DocetaxelTotal
United States182038
Argentina123
China10717
Korea, Republic of336
Eastern Oncology Cooperative Group (ECOG) Performance Status
Eastern Oncology Cooperative Group (ECOG) Performance Status(units on a scale)GemcitabineGemcitabine Plus DocetaxelTotal
0 - Fully Active121426
1 - Ambulatory, Restricted Strenuous Activity191837
2 - Ambulatory, No Work Activities101
08

Study locations

15 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    Denver, Colorado 80218, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    South Bend, Indiana 46601, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    Baltimore, Maryland 21237, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    Kalamazoo, Michigan 49048, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    Kansas City, Missouri 64128, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    St Louis, Missouri 63141, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    Cleveland, Ohio 44106, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    Portland, Oregon 97213, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    Philadelphia, Pennsylvania 19111, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    Memphis, Tennessee 38120, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    Rosario, 2000, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    Beijing, 100021, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    Chengdu, 610041, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    Seoul, 138-736, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph
    Suwon-City, 442-723, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003, a primary completion of Nov 2008 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Mar 2003
Primary completionActual
Nov 2008
CompletionActual
Feb 2009
Results first posted
Dec 25, 2009
Last update
Feb 17, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00191139
First posted
Sep 19, 2005
Start date
Mar 2003
Primary completion
Nov 2008
Completion
Feb 2009
Results posted
Dec 25, 2009
Last update
Feb 17, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Cisplatin · Etoposide

Start the discussion